Mon.Jan 08, 2024

article thumbnail

January 8, 2024: Pragmatic Trials Researchers Share Lessons From Collecting Patient-Reported Outcomes in the Electronic Health Record

Rethinking Clinical Trials

In a new article from the NIH Pragmatic Trials Collaboratory, investigators from 6 of the program’s pragmatic clinical trials share case examples of the challenges they encountered in collecting patient-reported outcomes (PROs) in their trials and the strategies they used to address them. The article was published this week in Contemporary Clinical Trials.

Trials 298
article thumbnail

JPM24: Nvidia’s AI dreams, Sarepta’s rosy outlook and Jeff Jonas’ new job

Bio Pharma Dive

The chip maker struck a new deal with Amgen on Monday, while Sarepta brought news of strong sales to the J.P. Morgan Healthcare Conference.

Sales 320
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sustainability in milling: A greener future for 2024?

Pharmaceutical Technology

With micronisation required for 30% of APIs on the market, there is a need for more sustainable methods of milling these vital drug products.

article thumbnail

Biogen CEO sees progress in launch of Alzheimer’s drug Leqembi

Bio Pharma Dive

At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now ‘not an issue’ for treatment.

Drugs 284
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA grants approval for Ligand’s molluscum contagiosum treatment

Pharmaceutical Technology

The FDA has granted approval for Ligand Pharmaceuticals’ Zelsuvmi (berdazimer topical gel, 10.3%) for molluscum contagiosum.

246
246
article thumbnail

Merck pays $680M for struggling cancer biotech Harpoon

Bio Pharma Dive

The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.

Marketing 276

More Trending

article thumbnail

5 questions facing emerging biotech in 2024

Bio Pharma Dive

An unusual FTC challenge could have implications for startups, while industry watchers are waiting to see if the sector’s recent momentum signals an end to a lengthy funding crunch.

227
227
article thumbnail

Senti Bio cuts 37% of workforce to free funds for cell therapy cancer trials

Pharmaceutical Technology

The layoffs and scaling back of R&D activities will extend Senti Biosciences' cash runway into Q1 2025, according to a press release.

Trials 162
article thumbnail

J&J to acquire ADC drug developer Ambrx for $2B

Bio Pharma Dive

The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

Drugs 198
article thumbnail

Curevo looks to challenge GSK’s Shingrix with positive Phase II data

Pharmaceutical Technology

Curevo’s shingles vaccine met all primary endpoints and was non-inferior to GSK’s Shingrix in a head-to-head Phase II trial.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Year of biotech layoffs leave industry looking for spark

Bio Pharma Dive

Small and mid-sized drugmakers shed at least 10,000 jobs in 2023, according to data compiled by BioPharma Dive, but recent deal, stock market momentum have brought some optimism.

Marketing 187
article thumbnail

NPPA to fix ceiling price of over 200 formulations based on market data of October, 2023

AuroBlog - Aurous Healthcare Clinical Trials blog

The National Pharmaceutical Pricing Authority (NPPA) is looking at fixing the ceiling prices of over 200 scheduled formulations under the Revised Schedule I of the Drugs (Prices Control) Order, 2013 based on the price database for the month of October, 2023.

Marketing 140
article thumbnail

JPM: Four ways FDA is seeking to buoy gene therapy

pharmaphorum

Dr Peter Marks, director of the FDA Center for Biologics Evaluation and Research told a packed house in San Francisco for JPM that FDA wants to support gene therapies in 2024.

article thumbnail

Novartis secures FDA approval for Pluvicto production at US plant

Pharmaceutical Technology

Novartis has received the US FDA approval to commercially manufacture Pluvicto at its new RLT manufacturing facility.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

JPM24: As cancer players jump head-first into ADC field, Novartis CEO explains how he's resisted the temptation

Fierce Pharma

San Francisco—Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. | Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation.

Antibody 117
article thumbnail

Boehringer and Kyowa Kirin sign fibro-inflammatory treatment deal  

Pharmaceutical Technology

Boehringer Ingelheim has signed a licensing agreement with Japan’s Kyowa Kirin to develop a new treatment for fibro-inflammatory diseases.

Licensing 130
article thumbnail

This week in clinical trials: 2nd-5th January 2024

pharmaphorum

Stay up to date with the latest developments in clinical trials, including updates on Vicore, Mundipharma, Agios, Ultragenyx, EG 427, Orion, and MSD. Find out what these companies are working on and their potential impact on healthcare.

article thumbnail

AlcoChange app to help alcohol-related liver disease patients stay sober

Pharma Times

Over a three-month period, 57% of patients using the app remained sober

112
112
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

JPM24: Bristol Myers Squibb CEO Boerner emphasizes organic pipeline over recent M&A deals

Fierce Pharma

It took Bristol Myers Squibb’s new CEO Chris Boerner 16 minutes into his 24-minute presentation to address the big news the company made last month, with its holiday

111
111
article thumbnail

Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt

pharmaphorum

Alphabet’s AI in drug discovery startup Isomorphic Labs signs collaborations with Eli Lilly and Novartis worth up to $3bn, its first two pharma partnerships

Drugs 110
article thumbnail

Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals

Drug Patent Watch

The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the… The post Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals appeared first on DrugPatentWatch - Make Better Decisions.

108
108
article thumbnail

12 Questions with Marcus West

pharmaphorum

This 12 Questions With Marcus West explores the 60 Seconds remote coaching app founder's journey into corporate coaching and how West realised his clients would improve faster if they dedicated themselves to ongoing microlearning in between coaching sessions.

109
109
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

JPM24: Merck expects $20B+ in post-Keytruda cancer sales thanks to Daiichi ADC deal, Moderna vaccine

Fierce Pharma

While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” | While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.

Sales 107
article thumbnail

Uptick in Clinical Trial Complexity: How Can You Achieve Your Clinical Trial Objectives Faster?

XTalks

Getting a drug to market used to be a relatively simple and straightforward affair. That’s just not the case anymore. Whether it’s for a treatment for a chronic ambulatory condition, precision medicine or cell and gene therapy, there is a massive uptick in clinical trial complexity. Most Phase II and Phase III studies have around 20 endpoints and 263 procedures per patient.

article thumbnail

Servier will apply ‘digital twin’ tech to Parkinson’s drug

pharmaphorum

Servier has added a third digital twin project to its collaboration with AI specialist Aitia, trying to identify Parkinson's patients who will respond to its LRRK2 inhibitor in clinical trials.

article thumbnail

Vicore Pharma’s DTx to benefit pulmonary fibrosis patients

Pharma Times

The nine-week DTxl CBT helps to address psychological symptom burdens in PF patients

104
104
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

JPM kicks off with takeovers by J&J, Novartis and MSD

pharmaphorum

JPM24 starts with three takeovers including J&J's $2bn bid for Ambrx, Merck’s $680m play for Harpoon Therapeutics and a $425m offer from Novartis for Calypso Biotech

102
102
article thumbnail

JPM24: Johnson & Johnson CEO says Tecvayli, Talvey and several other meds are set to trounce analyst estimates

Fierce Pharma

Johnson & Johnson is starting the year with a new corporate identi | Despite all the recent changes at Johnson & Johnson, the company maintains an aggressive outlook for its pharmaceuticals division. In fact, J&J's sales forecasts for some drugs come in vastly higher than analyst numbers.

Sales 102
article thumbnail

AUR-101 by Aurigene Oncology for Ankylosing Spondylitis (Bekhterev’s Disease): Likelihood of Approval

Pharmaceutical Technology

AUR-101 is under clinical development by Aurigene Oncology and currently in Phase II for Ankylosing Spondylitis (Bekhterev's Disease).

article thumbnail

Merck expands colorectal cancer portfolio through $45 million Inspirna deal

BioPharma Reporter

Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.